Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Shuhang WangHui-Yao HuangDawei WuHong FangJianming YingYing BaiYue YuYuan FangNing JiangChao SunAnqi YuQi FanShujun XingYufen NiWei ZhangChenhua WuXinqian JiHui WangYaqian GuoQiyu TangYuan WangYu TangNing LiPublished in: BMJ open (2021)
NCT04423185; ChiCTR2000039310.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- phase ii study
- double blind
- study protocol
- high throughput
- placebo controlled
- small cell lung cancer
- squamous cell carcinoma
- radiation therapy
- cancer therapy
- randomized controlled trial
- gene expression
- combination therapy
- genome wide
- locally advanced
- rectal cancer
- drug administration
- replacement therapy